Novelion Therapeutics Inc.

Michael Price has served as Novelion’s Senior Vice President and Chief Financial Officer since December 2017. Prior to Novelion, Michael Price was most recently vice president and chief financial officer for Noven Pharmaceuticals, Inc., a NASDAQ-listed company until its acquisition by Hisamitsu Pharmaceutical Company. In his role at Noven, Mr. Price was directly involved with the development and execution of strategy that scaled the Company’s commercial organization and significantly increased revenues. Prior to Noven, Mr. Price was vice president, chief financial officer, treasurer, secretary and a member of the board of directors for Bentley Pharmaceuticals, a New York Stock Exchange-listed company until Teva Pharmaceutical Industries’ 2008 acquisition. Mr. Price is a certified public accountant. He holds a bachelor of science degree in business administration (accounting) from Auburn University and a master of business administration degree from Florida State University.


Bank Name Novelion Therapeutics Inc.
Stock Exchange NASDAQ
Symbol NVLN
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
CEO Mr. Michael D. Price
Employees 180
Registered Year 1981